Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether low-doses alemtuzumab and rituximab combination are effective in the treatment of chronic graft-versus-host disease (GVHD) after first-line therapy failure.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
• Treatments: Alemtuzumab; Rituximab

Criteria

Inclusion Criteria:

• Patients with chronic graft-versus-host disease.

• Patients over 18 years old.

• Patients who received first-line treatment with no response (failure), relapse or steroid dependance.

Exclusion Criteria:

• Patients with active bacterial or viral infections.

• Patients with hematologic disease progression.

• Patient's intolerance to drugs.